About This Research Index

What Integrative Peptide is

Integrative Peptide is an independent editorial reference desk covering four metabolic and weight-management research peptides — AOD-9604, retatrutide, semaglutide, and tesamorelin — read the same way an analyst would read a set of trial reports: by study design, sample size, effect size, and confidence interval, not by marketing language. The organizing idea is a single integrated picture of metabolic research peptides: four different receptor-mechanism strategies aimed at overlapping metabolic outcomes, with retatrutide as the lead data set because it currently posts the largest published weight-loss figures of the four.

The four compounds sit at very different points on the evidence-maturity spectrum, and that is the point of reading them together rather than in isolation. Semaglutide has a decade-plus, multi-indication FDA approval built on tens of thousands of trial participants. Retatrutide has two large Phase 2 trials and a growing metabolomic literature but no Phase 3 confirmation yet. Tesamorelin has a narrow but solid approved indication. AOD-9604 has a clean rodent mechanism and a human trial program that measured safety successfully and efficacy unsuccessfully. Each page reports that maturity level plainly rather than smoothing it over.

How it is compiled

Three principles govern what appears here. First, every research claim is tied to a numbered citation on the references page: peer-reviewed journal articles, clinical-trial publications, and NIH or regulatory monographs, with DOIs or PubMed/PMC links wherever available. Second, results are reported at the scale and in the population they were actually studied in — a -24.2% weight-loss figure is reported as a 48-week, 338-person Phase 2 finding, not a universal claim, and a Phase 2 result is never described using approved-label language. Third, the four compound pages cross-reference each other and the comparison page, because the same underlying questions — mechanism, evidence maturity, regulatory status, key safety caution — recur across all four and are easiest to evaluate side by side.

What it is not

Integrative Peptide is not a pharmacy, a clinic, a telehealth service, or a vendor of any kind. It does not sell, source, or broker any compound, and it has no referral or affiliate relationship with any manufacturer, telehealth provider, or research-chemical supplier. It does not diagnose, prescribe, or recommend a dose, schedule, or route of administration for any individual.

Semaglutide and tesamorelin are approved prescription medicines available only through licensed medical providers. Retatrutide is investigational and legally available only within registered clinical trials. AOD-9604 was never approved for human use. Readers seeking clinical guidance should consult a licensed healthcare provider working with regulated, evidence-based options suited to their own situation. Editorial correspondence about citations, corrections, or newly published research can be directed to the contact page.